Permethrin


Generic Medicine Info
Contraindications
Hypersensitivity to permethrin, other pyrethroids, or pyrethrin.
Special Precautions
Scabies therapy: Persistent pruritus may be experienced after treatment; this reaction is usually not a sign of treatment failure and not a cause for re-treatment. Children (≥2 months) and elderly. Pregnancy and lactation. Patient Counselling Avoid contact with eyes or mucous membranes, or the area around the mouth (in children). Scabies therapy: As 5% cream/lotion: Do not go on a warm/hot bath before treatment; allow the skin to cool down prior to application. Carefully treat areas between skin folds or creases (e.g. between fingers and toes, wrist or waist folds, armpits, cleft of buttocks).
Adverse Reactions
Significant: Hypersensitivity reactions; may temporarily exacerbate symptoms, such as oedema, that accompany scabies (5% cream). General disorders and administration site conditions: Application site reactions (e.g. transient burning, numbness, stinging or tingling sensation). Nervous system disorders: Paraesthesia. Skin and subcutaneous tissue disorders: Pruritus, erythema, dry skin, rash.
Drug Interactions
Concomitant use with corticosteroids may increase the risk of exacerbating scabies infestation; hold corticosteroids before starting permethrin treatment.
CIMS Class
Topical Antifungals & Antiparasites
ATC Classification
P03AC04 - permethrin ; Belongs to the class of pyrethrines, including synthetic compounds used as ectoparasiticides.
Disclaimer: This information is independently developed by CIMS based on permethrin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in